Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study

This study was designed to evaluate whether subjects with amyloid beta (A beta) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without A beta pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (A beta+) or negative (A beta-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were A beta+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. A beta+ MCI subjects demonstrated greater worsening compared with A beta-subjects on the ADAS-Cog over 36 months (5.66 +/- 1.47 vs -0.71 +/- 1.09, P = 0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution (DSS) test, and a verbal fluency test (P < 0.05). Similar to MCI subjects, A beta+ CN subjects showed greater decline on the ADAS-Cog, digit-symbol-substitution test and verbal fluency (P < 0.05), whereas A beta+ AD patients showed greater declines in verbal fluency and the MMSE (P < 0.05). A beta+ subjects in all diagnostic groups also showed greater decline on the CDR-SB (P < 0.04), a global clinical assessment. A beta+ subjects did not show significantly greater declines on the ADCS-ADL or Wechsler Memory Scale. Overall, these findings suggest that in CN, MCI and AD subjects, florbetapir PET A beta+ subjects show greater cognitive and global deterioration over a 3-year follow-up than A beta- subjects do.